Abstract
Immunotherapy has demonstrated significant potential for the treatment of patients with hematologic malignancies and solid tumors. Among the many immunotherapy treatments, chimeric antigen receptor-T cell (CAR-T) therapy is the most promising treatment. The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. Currently, CAR-T therapy has many successful clinical results for hematologic malignancies. However, CAR-T has side effects and limits on anti-cancer effectiveness and persistence. Thus, a new CAR-T model is being developed to improve these problems. Although the new CAR-T model still needs more clinical trials, recent clinical trials have reported improvements over traditional CAR-T.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
